$1.12
-0.08 (-6.67%)
Open$1.20
Previous Close$1.20
Day High$1.20
Day Low$1.12
52W High$11.64
52W Low$1.15
Volume—
Avg Volume507.2K
Market Cap31.90M
P/E Ratio—
EPS$-2.14
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+1,406.3% upside
Current
$1.12
$1.12
Target
$16.87
$16.87
$11.09
$16.87 avg
$25.84
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 18.3K | 42.9K | 11.20M |
| Net Income | -55,175,308 | -116,321,801 | 1.78M |
| Profit Margin | -300,585.7% | -285,556.4% | 15.9% |
| EBITDA | -54,139,790 | -120,479,738 | 2.32M |
| Free Cash Flow | — | — | 977.1K |
| Rev Growth | -57.3% | -57.3% | +3.1% |
| Debt/Equity | — | — | 0.37 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |